Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, which is in a Phase I/II clinical trial for the treatment of lysosomal storage diseases with a focus on Pompe disease; and intravenous tramadol for the treatment of post-operative acute pain. It also develops AXS-17 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. operates as a subsidiary of Fortress Biotech, Inc.
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Most-followed names in the same sector.
Additional public equities from our tracked universe.
Large-cap symbols investors frequently compare.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Our full report includes a DCF valuation model, 5-year financial analysis, competitive moat assessment, risk factors, and a clear BUY / HOLD / SELL recommendation — the same analysis hedge funds pay thousands for.